d darunavir and etravirine both showed strong efficacy in clinical trials [7]???[10], and two medications representing novel ART classes???raltegravir and maraviroc [11], [12]???became widely available in the United States and particularly in San Francisco, aided by universal ART access programs.Although the full clinical impact of these new drugs remains undefined, emerging data suggest that the